Recordati Aktie - REC

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

48,50

Gebot

47,62

Fragen

48,84

Volumen

318.373

47,70 Tagesbereich 48,40

46,34 52-Wochen-Bereich 60,50

Marktkapitalisierung

9,96B

Handelsende

48,36

Handelsbeginn

48,20

Letzte Trade

48.5

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

452.005

Ausgegebene Aktien

205.358.104

Dividendenrendite

2.47%

Kurs-Gewinn-Verhältnis

25,85

Gewinn pro Aktie (EPS)

1,9

Erlöse

2,07B

Nettogewinn

389,21M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.recordati.it

Hauptsitz

Milan, Lombardy, Ita

Gegründet

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italienische Börse with ticker REC. The last closing price for Recordati was 48,36 €. Over the last year, Recordati shares have traded in a share price range of 46,34 € to 60,50 €.

Recordati currently has 205.358.104 shares in issue. The market capitalisation of Recordati is 9,93 € billion. Recordati has a price to earnings ratio (PE ratio) of 25.85.

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.7	1.46443514644	47.8	48.4	47.12	317263	47.97775864	DE
4	-5.3	-9.85130111524	53.8	54.3	46.34	433747	51.008725	DE
12	-6.65	-12.0580235721	55.15	60.5	46.34	452005	54.30675023	DE
26	-4.6	-8.66290018832	53.1	60.5	46.34	351851	53.40586107	DE
52	-0.92	-1.86159449616	49.42	60.5	46.34	296380	52.09735438	DE
156	0.69	1.443212717	47.81	60.5	34.52	249741	46.74942133	DE
260	9.93	25.7453979777	38.57	60.5	34.52	274071	46.63580071	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 48,50 €

How many Recordati shares are in issue?

Recordati has 205.358.104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 9,93B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 46,34 € to 60,50 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 25,85

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 4,87

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2,07B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 389,21M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
BIABialetti Industrie Spa	0,45 € (61,29%)	6,72M
WHIK26Haiki Spa	0,0838 € (38,51%)	3,5k
WS3D25Solid World Group spa	0,045 € (34,73%)	26,25k
PREPredict SpA	0,89 € (20,27%)	330k
XHSXenia Hotellerie Solution SpA Societa Benefit	3,60 € (20,00%)	33,5k
WSOS26Sostravelcom SpA	0,0214 € (-47,55%)	13,6k
FDAFidia	0,0054 € (-18,18%)	18,73M
MTVFRMondo TV France	0,0045 € (-10,00%)	182k
TDTrenDevice Spa	0,11 € (-8,33%)	126k
1AMDAdvanced Micro Devices Inc	78,97 € (-7,09%)	15,51k
TITTelecom Italia SpA	0,3216 € (1,48%)	362,69M
ISPIntesa Sanpaolo Spa	4,3955 € (0,91%)	63,96M
SPMSaipem Spa	1,8195 € (1,03%)	37,76M
TITRTelecom Italia	0,3699 € (2,35%)	33,81M
STLAMStellantis NV	8,225 € (-1,13%)	28,35M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Recordati SpA (REC)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Recordati SpA

REC Neueste Nachrichten

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Beweger

REC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Recordati SpA (REC) Börsenkurse

Recordati SpA (REC)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Recordati SpA

REC Neueste Nachrichten

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Beweger

REC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen